NASDAQ$RPRX
Royalty Pharma PLC · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Royalty Pharma plc reported increased total income and other revenues for the second quarter ended June 30, 2025.
Royalty Pharma achieved total income and other revenues of $578.7 million in Q2 2025, reflecting 7.7% growth driven by key royalty assets including the cystic fibrosis franchise and Voranigo. Operating income reached $209.8 million while net income attributable to shareholders was $30.2 million. The company completed the internalization of its external manager during the quarter, resulting in higher general and administrative expenses.
- Total income and other revenues grew 7.7% year-over-year to $578.7 million, led by the cystic fibrosis franchise and new contributions from Voranigo.
- Operating income was $209.8 million after recording a $300.5 million R&D funding expense and internalization-related costs.
- Net income attributable to Royalty Pharma plc was $30.2 million, or $0.07 per diluted Class A ordinary share.
- Cash and cash equivalents stood at $631.9 million at quarter end, supporting ongoing royalty acquisitions and debt management.
Headline financials
Revenue & EPS history
Royalty Pharma · Revenue · Quarterly
$579M
Revenue by segment
Royalty Pharma · $687M total across 13 segments · Q3 2023
- Cystic Fibrosis Franchise$238M+14.4%34.6%
- Tysabri$87M-4.4%12.7%
- Imbruvica$62M-16.2%9.0%
- Trelegy$58M+34.9%8.4%
- Promacta$54M+8.0%7.9%
- Xtandi$47M+2.2%6.8%
- Other Products$46M-37.0%6.7%
- Tremfya$27M+28.6%3.9%
- Cabometyx/Cometriq$17M+13.3%2.5%
- Evrysdi$16M+60.0%2.3%
- Spinraza$15M—2.2%
- Trodelvy$11M+83.3%1.6%
- Erleada$9M+50.0%1.3%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-0.6%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+0.9%
Avg return
30 days after
43%
10 / 23 earnings
Positive
+6.8%
Q3 2025
Best reaction
-8.1%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -1.0% | +2.4% | +10.7% | |
| Q4 2025 | +0.1% | +2.2% | +3.3% | |
| Q3 2025 | +6.8% | +1.8% | +5.0% | |
| Q1 2025 | +0.9% | +0.2% | +3.1% | |
| Q4 2024 | +1.7% | +2.0% | +3.0% | |
| Q3 2024 | -3.7% | -4.3% | -5.9% | |
| Q2 2024 | -3.6% | -1.4% | +5.3% | |
| Q1 2024 | +0.4% | +0.3% | -1.9% | |
| Q4 2023 | +2.1% | +3.4% | +2.7% | |
| Q3 2023 | -0.5% | -1.6% | +3.7% | |
| Q2 2023 | -0.9% | -1.1% | -6.4% | |
| Q1 2023 | -4.7% | -2.7% | -2.8% | |
| Q4 2022 | -2.0% | -0.4% | -8.8% | |
| Q3 2022 | +1.6% | +3.7% | -0.1% | |
| Q2 2022 | -0.9% | +1.9% | -1.8% | |
| Q1 2022 | -8.1% | -12.8% | -6.2% | |
| Q4 2021 | +3.6% | +0.8% | +1.7% | |
| Q3 2021 | +1.5% | +5.3% | -4.6% | |
| Q2 2021 | +2.7% | +5.0% | +5.6% | |
| Q1 2021 | -2.2% | -1.8% | +12.4% | |
| Q4 2020 | -2.1% | +1.1% | -1.5% | |
| Q3 2020 | -1.6% | +2.8% | +10.3% | |
| Q2 2020 | -3.0% | -4.2% | -5.9% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro